ABIVAX Société Anonyme (NASDAQ:ABVX - Get Free Report) gapped up before the market opened on Thursday after Morgan Stanley raised their price target on the stock from $15.00 to $16.00. The stock had previously closed at $15.39, but opened at $15.81. Morgan Stanley currently has an equal weight rating on the stock. ABIVAX Société Anonyme shares last traded at $16.09, with a volume of 15,974 shares trading hands.
Institutional Investors Weigh In On ABIVAX Société Anonyme
Several institutional investors and hedge funds have recently made changes to their positions in ABVX. Nantahala Capital Management LLC acquired a new position in ABIVAX Société Anonyme in the fourth quarter worth $10,807,000. Great Point Partners LLC bought a new position in shares of ABIVAX Société Anonyme in the 4th quarter worth about $16,585,000. Blackstone Inc. acquired a new position in shares of ABIVAX Société Anonyme in the 4th quarter valued at about $25,345,000. Citadel Advisors LLC bought a new stake in shares of ABIVAX Société Anonyme during the 4th quarter valued at about $7,842,000. Finally, Commodore Capital LP bought a new stake in shares of ABIVAX Société Anonyme during the 4th quarter valued at about $20,277,000. 47.91% of the stock is owned by institutional investors and hedge funds.
ABIVAX Société Anonyme Trading Down 2.5 %
The stock has a 50 day moving average price of $13.74.
About ABIVAX Société Anonyme
(
Get Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.
Featured Stories
Before you consider ABIVAX Société Anonyme, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABIVAX Société Anonyme wasn't on the list.
While ABIVAX Société Anonyme currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
